242 related articles for article (PubMed ID: 15846059)
21. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
22. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Albo D; Berger DH; Rothman VL; Tuszynski GP
J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
[TBL] [Abstract][Full Text] [Related]
23. Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.
Dutta S; Bandyopadhyay C; Bottero V; Veettil MV; Wilson L; Pins MR; Johnson KE; Warshall C; Chandran B
Mol Oncol; 2014 May; 8(3):483-507. PubMed ID: 24457100
[TBL] [Abstract][Full Text] [Related]
24. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Magdolen V; Krüger A; Sato S; Nagel J; Sperl S; Reuning U; Rettenberger P; Magdolen U; Schmitt M
Recent Results Cancer Res; 2003; 162():43-63. PubMed ID: 12790320
[TBL] [Abstract][Full Text] [Related]
26. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
Moreau M; Mourah S; Dosquet C
Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
[TBL] [Abstract][Full Text] [Related]
27. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
28. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
29. In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
Luparello C; Del Rosso M
Eur J Cancer; 1996 Apr; 32A(4):702-7. PubMed ID: 8695276
[TBL] [Abstract][Full Text] [Related]
30. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
Mazumdar A; Adam L; Boyd D; Kumar R
Cancer Res; 2001 Jan; 61(1):400-5. PubMed ID: 11196194
[TBL] [Abstract][Full Text] [Related]
31. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.
Conese M; Blasi F
Biol Chem Hoppe Seyler; 1995 Mar; 376(3):143-55. PubMed ID: 7612191
[TBL] [Abstract][Full Text] [Related]
32. Maspin, the molecular bridge between the plasminogen activator system and beta1 integrin that facilitates cell adhesion.
Endsley MP; Hu Y; Deng Y; He X; Warejcka DJ; Twining SS; Gonias SL; Zhang M
J Biol Chem; 2011 Jul; 286(28):24599-607. PubMed ID: 21606500
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
34. Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion.
Khanna M; Wang F; Jo I; Knabe WE; Wilson SM; Li L; Bum-Erdene K; Li J; W Sledge G; Khanna R; Meroueh SO
ACS Chem Biol; 2011 Nov; 6(11):1232-43. PubMed ID: 21875078
[TBL] [Abstract][Full Text] [Related]
35. Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.
Mani T; Wang F; Knabe WE; Sinn AL; Khanna M; Jo I; Sandusky GE; Sledge GW; Jones DR; Khanna R; Pollok KE; Meroueh SO
Bioorg Med Chem; 2013 Apr; 21(7):2145-55. PubMed ID: 23411397
[TBL] [Abstract][Full Text] [Related]
36. maspin suppresses the invasive phenotype of human breast carcinoma.
Seftor RE; Seftor EA; Sheng S; Pemberton PA; Sager R; Hendrix MJ
Cancer Res; 1998 Dec; 58(24):5681-5. PubMed ID: 9865722
[TBL] [Abstract][Full Text] [Related]
37. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
Kunigal S; Lakka SS; Gondi CS; Estes N; Rao JS
Int J Cancer; 2007 Nov; 121(10):2307-16. PubMed ID: 17657740
[TBL] [Abstract][Full Text] [Related]
38. A role of novel serpin maspin in tumor progression: the divergence revealed through efforts to converge.
Sheng S
J Cell Physiol; 2006 Dec; 209(3):631-5. PubMed ID: 17001674
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway.
Gondi CS; Kandhukuri N; Dinh DH; Gujrati M; Rao JS
Int J Oncol; 2007 Jul; 31(1):19-27. PubMed ID: 17549401
[TBL] [Abstract][Full Text] [Related]
40. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.
Reuning U; Sperl S; Kopitz C; Kessler H; Krüger A; Schmitt M; Magdolen V
Curr Pharm Des; 2003; 9(19):1529-43. PubMed ID: 12871066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
